Zydus Cadila obtains final USFDA nod for Albuterol tablets; stock up by 2 per cent

Zydus Cadila informed the exchanges today that it has received final approval from United States Food & Drug Administration (USFDA) to market Albuterol tablets in the strengths of 2 mg and 4 mg, which is bioequivalent of reference listed drug (RLD) Proventil tablets.

Albuterol is a bronchodilator, which helps open up the airways in the lungs and makes it easier to breathe. The medicine is used to treat as well as prevent Bronchospasm. The company stated in the press release to the exchanges that the drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.

Cadila Healthcare Limited operates in the areas of active pharmaceutical ingredients (APIs) to formulations, and animal health products to cosmeceuticals. The group now has around 310 approvals and so far, filed 390 abbreviated new drug applications (ANDAs).

At 12.30 pm on Friday, the stock of Cadila Healthcare was trading at Rs 432.70 per share, up by 1.72 per cent or Rs 7.30 per share on BSE. Its 52-week high is recorded at Rs 447.95 and the 52-week low is Rs 212.70 on BSE.